Viking Global Reduces BridgeBio Pharma Stake by $81M; Director Ott Retires
Summary
Viking Global Investors LP and its affiliates reported selling approximately $81.28 million worth of BridgeBio Pharma common stock in February 2026, reducing their beneficial ownership to 6.1%. The filing also notes the retirement of David C. Ott as a reporting person.
Key Events
-
Significant Stock Sales
Viking Global Investors LP and its affiliates sold 1,183,933 shares of BridgeBio Pharma common stock between February 18 and February 23, 2026, for an aggregate value of approximately $81.28 million.
-
Reduced Ownership Stake
Following these transactions, Viking Global Investors LP and its affiliates now beneficially own 11,842,434 shares, representing 6.1% of BridgeBio Pharma's outstanding common stock.
-
Director Retirement
David C. Ott was removed as a reporting person from the Schedule 13D due to his retirement from Viking Global Investors LP and its related entities, effective March 31, 2026.
Analysis
This Schedule 13D/A indicates a significant reduction in holdings by institutional investor Viking Global Investors LP and its affiliates, who sold over $81 million in BridgeBio Pharma stock in February 2026. While these sales occurred prior to the company's recent positive drug data and NDA submission in late March, the disposition by a major institutional holder is a notable event. The reduction in stake, alongside the removal of David C. Ott as a reporting person due to his retirement, suggests a re-evaluation or rebalancing of the investment by Viking Global. Investors should monitor future filings for further changes in institutional ownership.
At the time of this filing, BBIO was trading at $73.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2B. The 52-week trading range was $28.33 to $84.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.